CureVac Acquisition Enters Final Phase as Shareholder Vote Concludes

The timeline for CureVac's corporate existence is drawing to a close following resounding shareholder approval of BioNTech's acquisition proposal. Investors now face critical deadlines to exchange their holdings, with the stock demonstrating unexpected strength during its final trading sessions.

During an extraordinary general meeting convened on November 25, 2025, CureVac shareholders delivered a decisive verdict. An impressive 99.16% of voting participants endorsed BioNTech's public share exchange offer, effectively sealing the company's fate as an independent publicly-traded entity. The transaction had previously received clearance from Germany's Federal Cartel Office, removing the final regulatory obstacle.

This decisive outcome provides clarity to the investment community while simultaneously creating urgency for current shareholders to take specific actions within defined time parameters.

Critical Timelines for Shareholder Action

Investors maintaining CureVac positions in their portfolios should carefully note these approaching deadlines:

Should investors sell immediately? Or is it worth buying CureVac?

• Submission Deadline: Shareholders must submit their CureVac holdings by December 2, 2025, at 6:00 PM Eastern Time
• Offer Expiration: The official exchange offer concludes on December 3, 2025, at 9:00 AM Eastern Time
• Exchange Ratio: The conversion rate establishes that each CureVac share will be exchanged for 0.05363 BioNTech ADRs

With this fixed conversion mechanism now confirmed, CureVac's valuation has become fundamentally linked to BioNTech's share performance. Arbitrage opportunities have largely evaporated as market pricing fully reflects the transaction's certainty.

Unexpected Technical Strength Emerges

Interestingly, CureVac's equity demonstrated notable resilience on November 26, surpassing its 100-day moving average and reaching approximately $5.48. This technical breakout signal emerged despite the imminent conclusion of the company's independent trading history. Market observers attribute this movement to final position adjustments by institutional investors or speculative activity anticipating smooth settlement procedures.

Final Financial Reporting Before Merger

Coinciding with the acquisition process, CureVac disclosed its third-quarter 2025 financial results. The company reported net profitability despite significantly reduced revenues, which reflected the absence of one-time payments recorded in previous periods. While these earnings primarily resulted from comparative accounting effects, they indicate CureVac enters the merger with a cleaned-up balance sheet. For shareholders, these fundamental metrics have become largely irrelevant, with successful share conversion now representing the primary consideration.

The corporate transition marks the conclusion of CureVac's independent market presence, with investors now focused exclusively on the mechanical process of exchanging their shares before the established deadlines.